

ACG's IBD School 2017

8:00 am – 5:30 pm

Friday, August 25, 2017

Hilton at the Ballpark

St. Louis, Missouri

Course Directors:

Sunanda V. Kane, MD, MSPH, FACG

Disclosures: Consultant: AbbVie, Samsung Bioepis, Arabella Associates, 11Health, Janssen

Research funding: UCB

Other: ABIM GI Specialty Board

David T. Rubin, MD, FACG

Disclosures: Consultant/Grant Support: AbbVie, Amgen, Celgene, Emmi, Forward Pharma, Genentech/Roche, Janssen, Pfizer, Prometheus, Sandoz, Shire, Takeda

Board Membership: ACG Institute Board of Trustees, ACG Board of Trustees, Cornerstones Health, Inc

Up to 9 hours of CME & 9 MOC points

- 7:00 am **Registration and Continental Breakfast**
- 8:00 am **Welcome and Introduction**
Jean-Paul Achkar, MD, FACG
- 8:10 am **Understanding the Epidemiology and Natural History of IBD for Clinicians**
Edward V. Loftus, Jr., MD, FACG
Describe the epidemiology and natural history of IBD, the theories regarding its development, and differentiate IBD from its mimics.
- 8:30 am **Thoughtful Application of Diagnostic Tools in IBD: When to Use What**
Russell D. Cohen, MD, FACG
Discuss the appropriateness and timing of various diagnostic tools in IBD and review pearls for their proper use.
- 9:00 am **Goals of Caring for the IBD Patient**
Jean-Paul Achkar, MD, FACG
Analyze the available data and positioning in IBD management of patient-centered goals and published algorithms of care.
- 9:30 am **How to Think About Immune Suppressive Agents in the Era of Biologics**
Matthew A. Ciorba, MD
Explain the roles and positioning of immune suppressive agents including steroids, thiopurines, methotrexate, and tacrolimus.
- 10:00 am **Q & A**
- 10:15 am **Refreshment Break**
- 10:35 am **Biological Therapies in IBD: The Revolution in IBD**
Stephen B. Hanauer, MD, FACG
Recognize the role of biologics including appropriate candidates, the various mechanisms of action, and data to support each.
- 11:15 am **Drug and Disease Monitoring**
Jean-Paul Achkar, MD, FACG
Critically analyze the available data supporting therapeutic drug monitoring, recommendations for pre-therapy testing, and proactive management while receiving therapies.

- 11:40 am **Timing of Surgery and Prevention of Post-operative Recurrence**
Stephen B. Hanauer, MD, FACC
Outline the management of patients who are surgical candidates, and describe the management of patients in the post-operative period.
- 11:55 am **Lunch with Faculty and Case Presentations**
All faculty
- 1:30 pm **Cancer Prevention in IBD**
Edward V. Loftus, Jr., MD, FACC
Summarize primary and secondary cancer prevention in IBD patients, including the use of chromoendoscopy.
- 1:55 pm **Management of EIM: Disease-related, Disease-unrelated, and Therapy-related**
Laura H. Yun, MD
Identify non-gastrointestinal conditions associated with IBD and their management.
- 2:20 pm **Complementary and Alternative Medicine in IBD**
Matthew A. Ciorba, MD
Interpret the evidence base for popular alternative therapies including medical marijuana, herbal remedies, and probiotics.
- 2:45 pm **Refreshment Break**
- 3:00 pm **Diet and Nutrition**
Russell D. Cohen, MD, FACC
Outline the evidence for different diets in managing patients with IBD.
- 3:25 pm **The Pregnant Patient With IBD**
Laura H. Yun, MD
Discuss IBD management strategies before and during pregnancy.
- 3:50 pm **Microscopic Colitis**
Edward V. Loftus, Jr., MD, FACC
Discuss the epidemiology and management of microscopic colitis
- 4:15 pm **Case Presentations**
All faculty
- 5:15 pm **Q & A / Wrap-up**
Jean-Paul Achkar, MD, FACC
- 5:30 pm **Adjourn**